INCYTE CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 59.02 USD | -3.04% |
|
-6.47% | -6.00% |
| 07-02 | S&P 500, Nasdaq Close at Record Highs After Fed Chair Powell's Comments | MT |
| 07-02 | S&P 500, Nasdaq Close at Record Highs After Fed Chair Powell's Comments | MT |
Presenter SpeechSalveen Richter (Analysts)Good morning, everyone, and Happy New Year. And than...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Sector
Pharmaceuticals
Calendar
2024-07-29
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
59.02
USD
Average target price
72.62
USD
Spread / Average Target
+23.04%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.00% | 13.27B | |
| +6.58% | 41.61B | |
| -11.57% | 33.32B | |
| +79.15% | 28.8B | |
| -14.73% | 15.61B | |
| -12.55% | 11.46B | |
| +166.50% | 10.06B | |
| -54.80% | 9.09B | |
| +4.19% | 8.9B | |
| -11.11% | 7.79B |
- Stock Market
- Equities
- INCY Stock
- News Incyte Corporation
- Transcript : Incyte Corporation Presents at Goldman Sachs Healthcare C-Suite Unscripted Conference, Jan-04-2024 09
